The production of the drug AstraZeneca was suspended to eliminate public mistrust of vaccines and to accelerate the pace of vaccination. The biotech company Emergent BioSolution will now focus on Johnson & Johnson's single-component vaccine to avoid further technological errors.
"AstraZeneca, meanwhile, announced that it is looking for another place for the production of its drug", - said the Interfax agency. The vaccine from AstraZeneca in the last month has repeatedly shown itself not in the best way in Europe, Georgia and Israel. There have been cases of death of patients after vaccination, including young vaccinated. Many also began to form blood clots.
In a number of European countries, the authorities have decided to suspend its use. At the same time, Johnson & Johnson's vaccine is one of three used in the United States along with drugs from Pfizer and Moderna. The AstraZeneca vaccine has not yet received approval for use in the United States, RIA Novosti reports.